Selected studies of high-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma (PTCL).
| Study Group/Country . | N . | Med age . | Risk factors . | Histologies . | Pre-regimens . | Status . | F/U mos . | OS (mo) . | EFS/DFS/PFS (mo) . | TRM/NRM, % . |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: HDS, high-dose sequential therapy; ACVB, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; NCVB, mitoxantrone, cyclophosphamide, vindesine, bleomycin, prednisone; HSTCL, hepatosplenic t-cell lymphoma; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; CHOEP, CHOP plus etoposide; ESHAP, etoposide, cisplatin, cytarabine, prednisone; PTCL-NOS, PTCL-not otherwise specified; ALCL, aplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; EATCL, enteropathy-associated T-cell lymphoma; CR, complete remission; PR, partial remission; POD, progression of disease | ||||||||||
| GEL-TAMO (2003)53 | 115 | 41 | AA-IPI 0–1 40% 2–3 60% | PTCL-NOS=62.6% ALCL-21.8% AITL-5.2% | Various PR/CR>1 62% Refr 6% | CR1-32% | 37 | 56 | 60 | 8 |
| GEL-TAMO-CR1 (2007)25 | 74 | 46 | AA-IPI 2–3 65% | PTCL-NOS 50% ALCL-31% AITL-11% | CHOP-72% | CR1 | 67 | 68 | 63 | 4 |
| BSBMT/ABMTRR (2007)26 | 64 | 45 | IPI Unknown 42% 0–1 59% 2 19% 3–4 22% | ALCL-31% (+/−) PTCL-47% AITL-8% | Various | CR1-48% CR2-6%, PR-23% POD-22% | 37 | 53 | 50 | 15 |
| Finland (2004)27 | 37 | 46 | IPI 0–1 46% 2 22% 3–4 30% | ALCL-38% PTCL-38% EATCL-14% | Various | CR/PR1-49% CR/PR2-38 | 24 | 54 | 46 | 11 |
| Italy (2006)36 | 62 | 43 | AA-IPI 0–1 29% 2–3 71% | PTCL-45% ALCL+ 30% AITL 16% | HDS MACOP-B | CR1-35 PR1-10 | 76 | 34 (21) | 30 (19) | 4.8 |
| GELA (2004)54 | 28 | 36 | AA-IPI 0–1 25% 2–3 75% | Non-ALCL-100% | ACVB NCVB | CR/CRu-100% | 78 | 54 | 44 | NR |
| GELCAB (2008)32 | 41 | 47 | 0–1 22% 2 32% 3 22% 4–5 24% | PTCL 49% AITL 29% HSTCL 5% NK nasal 5% other 12% | High-dose CHOP + ESHAP | CR/CRu 49% PR 10% | 38 | 39 | 30 | NR |
| EBMT (2008)55 | 146 | 53 | NR | AITL 100% | Various | CR1 34% CR2 14% PR 36% | 31 | 59 | 42 | 7 |
| Nordic (2006)35 | 121 | 55 | IPI 0–2 46% 3–4 54% | PTCL 41% AITL 17% Alk-ALCL 23% EATCL 12% Other 7% | CHOEP | CR/CRu 50% PR 37% | 24 | 67 | NR | 4 |
| Study Group/Country . | N . | Med age . | Risk factors . | Histologies . | Pre-regimens . | Status . | F/U mos . | OS (mo) . | EFS/DFS/PFS (mo) . | TRM/NRM, % . |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: HDS, high-dose sequential therapy; ACVB, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; NCVB, mitoxantrone, cyclophosphamide, vindesine, bleomycin, prednisone; HSTCL, hepatosplenic t-cell lymphoma; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; CHOEP, CHOP plus etoposide; ESHAP, etoposide, cisplatin, cytarabine, prednisone; PTCL-NOS, PTCL-not otherwise specified; ALCL, aplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; EATCL, enteropathy-associated T-cell lymphoma; CR, complete remission; PR, partial remission; POD, progression of disease | ||||||||||
| GEL-TAMO (2003)53 | 115 | 41 | AA-IPI 0–1 40% 2–3 60% | PTCL-NOS=62.6% ALCL-21.8% AITL-5.2% | Various PR/CR>1 62% Refr 6% | CR1-32% | 37 | 56 | 60 | 8 |
| GEL-TAMO-CR1 (2007)25 | 74 | 46 | AA-IPI 2–3 65% | PTCL-NOS 50% ALCL-31% AITL-11% | CHOP-72% | CR1 | 67 | 68 | 63 | 4 |
| BSBMT/ABMTRR (2007)26 | 64 | 45 | IPI Unknown 42% 0–1 59% 2 19% 3–4 22% | ALCL-31% (+/−) PTCL-47% AITL-8% | Various | CR1-48% CR2-6%, PR-23% POD-22% | 37 | 53 | 50 | 15 |
| Finland (2004)27 | 37 | 46 | IPI 0–1 46% 2 22% 3–4 30% | ALCL-38% PTCL-38% EATCL-14% | Various | CR/PR1-49% CR/PR2-38 | 24 | 54 | 46 | 11 |
| Italy (2006)36 | 62 | 43 | AA-IPI 0–1 29% 2–3 71% | PTCL-45% ALCL+ 30% AITL 16% | HDS MACOP-B | CR1-35 PR1-10 | 76 | 34 (21) | 30 (19) | 4.8 |
| GELA (2004)54 | 28 | 36 | AA-IPI 0–1 25% 2–3 75% | Non-ALCL-100% | ACVB NCVB | CR/CRu-100% | 78 | 54 | 44 | NR |
| GELCAB (2008)32 | 41 | 47 | 0–1 22% 2 32% 3 22% 4–5 24% | PTCL 49% AITL 29% HSTCL 5% NK nasal 5% other 12% | High-dose CHOP + ESHAP | CR/CRu 49% PR 10% | 38 | 39 | 30 | NR |
| EBMT (2008)55 | 146 | 53 | NR | AITL 100% | Various | CR1 34% CR2 14% PR 36% | 31 | 59 | 42 | 7 |
| Nordic (2006)35 | 121 | 55 | IPI 0–2 46% 3–4 54% | PTCL 41% AITL 17% Alk-ALCL 23% EATCL 12% Other 7% | CHOEP | CR/CRu 50% PR 37% | 24 | 67 | NR | 4 |